AVDL · As filed with the SEC
Avadel Pharmaceuticals income statement, by quarter
The statement as Avadel Pharmaceuticals presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|
| Net product revenue | 77,467 | 68,129 | 52,511 | 50,410† | 50,025 |
| Cost of products sold | (4,116) | — | — | — | — |
| Cost of products sold | (4,116)† | 6,366 | 5,577 | 4,812† | 6,155 |
| Gross profit | 81,583 | 61,763 | 46,934 | 45,598† | 43,870 |
| Operating expenses: | |||||
| Research and development expenses | 27,010 | 4,255 | 4,354 | 4,274† | 3,803 |
| Selling, general and administrative expenses | 52,636 | 48,624 | 45,581 | 44,621† | 40,394 |
| Total operating expense | 79,646 | 52,879 | 49,935 | 48,895† | 44,197 |
| Operating income (loss) | 1,937 | 8,884 | (3,001) | (3,297)† | (327) |
| Investment and other income, net | 532 | (34) | 397 | 1,036† | 610 |
| Interest expense | (2,415) | (2,355) | (2,238) | (2,702)† | (2,820) |
| Loss on extinguishment of debt | — | — | — | 0† | 0 |
| Income (loss) before income taxes | 54 | 6,495 | (4,842) | (4,963)† | (2,537) |
| Income tax provision (benefit) | 34 | (3,170) | 78 | 80† | 88 |
| Net income (loss) | 20 | 9,665 | (4,920) | (5,043)† | (2,625) |
| Net income (loss) per share - basic (in dollars per share) | 0.00 | 0.10 | (0.05) | — | (0.03) |
| Net income (loss) per share - diluted (in dollars per share) | 0.00 | 0.10 | (0.05) | — | (0.03) |
| Weighted average number of shares outstanding - basic (in shares) | 97,104 | 96,726 | 96,601 | — | 96,300 |
| Weighted average number of shares outstanding - diluted (in shares) | 101,276 | 99,087 | 96,601 | — | 96,300 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.